SLNO241220P20000
- 0.50
- 0.000.00%
Soleno Therapeutics Newsroom
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Soleno Drew an Initial $50M at Closing
Express News | Soleno Therapeutics Enters Into $200 Million Debt Financing With Oxford Finance LLC
Press Release: Soleno Therapeutics Enters Into $200 Million Debt Financing With Oxford Finance LLC
Insiders At Soleno Therapeutics Sold US$19m In Stock, Alluding To Potential Weakness
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $74
Soleno Therapeutics Weakness a Buying Opportunity, Says Baird
Express News | HC Wainwright & Co. Reiterates Buy on Soleno Therapeutics, Maintains $70 Price Target
Confident Buy Rating on Soleno Therapeutics Amidst Imminent FDA Approval and Strong Valuation
Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $72
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Soleno Therapeutics Says FDA Extends DCCR NDA Review Citing 'Major Amendment'
Express News | Soleno Therapeutics Shares Slide 13% Premarket After Co Announces US FDA Extension of Review Period for Genetic Disorder Treatment
Soleno Therapeutics Announces U.S.. FDA to Ended Review Period for NDA
Express News | Soleno: FDA Determined That Responses to Recent Information Requests Constituted a Major Amendment to Nda for Dccr Extended-Release Tablets
Express News | Soleno Therapeutics Inc - FDA Did Not Cite Safety, Efficacy or Manufacturing Concerns
Express News | Soleno Therapeutics Inc - New Pdufa Target Action Date Set for March 27, 2025
Soleno Therapeutics Reports Q3 Progress and Financials
Express News | Soleno Therapeutics Announces Oral Presentations Featuring Diazoxide Choline Extended-Release (Dccr) Tablets in Prader-Willi Syndrome at Espe 2024
H.C. Wainwright Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $70